thus the importance of understanding the MOA this could validate a lot of the claims that were rejected. So basically MOA not required for Pharma or FDA but potentially for a patent.
Side note, they didn’t agree that Bisantrene self rescues but rather it was just heart safe to begin with. Thus more work for Dr Jensen to firm up.
Also ARA-C previously released so prior art unless something more novel is identified. And more proof to expand to all anthracyclines and herceptin per the triangle report.
General Comments / Chat, page-7706
-
- There are more pages in this discussion • 3,583 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
